Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Y T Liu

Showing results (211-220 of 227) with videos related to

Pageof 23
Sort By:
Zhonghua Xue Ye Xue Za Zhi = Zhonghua Xueyexue Zazhi|May 24, 2016
[Cytogentic and prognostic characteristic of acute myeloid leukemia with monosomal karyotype]Z Li, H Wei, D Lin, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 31, 2022
Validation of the Decipher genomic classifier in patients receiving salvage radiotherapy without hormone therapy after radical prostatectomy - an ancillary study of the SAKK 09/10 randomized clinical trialA Dal Pra, P Ghadjar, S Hayoz, et al.
Zhonghua Xue Ye Xue Za Zhi = Zhonghua Xueyexue Zazhi|July 4, 2021
[The characteristics and prognostic impact of NOTCH1/FBXW7 mutation and CDKN2A/B deletion in adult T-cell acute lymphoblastic leukemia patients]Q Y Fang, Q S Hao, X Y Gong, et al.
Zhonghua Xue Ye Xue Za Zhi = Zhonghua Xueyexue Zazhi|July 6, 2026
[Prognostic impact of WT1 mutations in patients with acute myeloid leukemia]Y Zeng, Y Hui, L Yan, et al.
Zhonghua Xue Ye Xue Za Zhi = Zhonghua Xueyexue Zazhi|March 19, 2018
[Characteristics and prognosis in adult acute myeloid leukemia patients with MLL gene rearrangements]X Y Gong, Y Wang, B C Liu, et al.
The Review of Scientific Instruments|December 3, 2016
An instrument for measuring scintillators efficiently based on silicon photomultipliersM J Yang, Z M Zhang, Y J Wang, et al.
International Journal of Radiation Oncology, Biology, Physics|September 25, 2024
Erratum to: Spratt DE, Liu VYT, Michalski J, Davicioni E, Berlin A, Simko JP, Efstathiou JA, Tran PT, Sandler HM, Hall WA, Thompson DJS, Parliament MB, Dayes IS, Correa RJM, Robertson JM, Gore EM, Doncals DE, Vigneault E, Souhami L, Karrison TG, Feng FY. Genomic classifier performance in intermediate-risk prostate cancer: results from NRG Oncology/RTOG 0126 randomized phase 3 trial. Int J Radiat Oncol Biol Phys 2023;117:370-377Daniel E Spratt, Vinnie Y T Liu, Jeff Michalski, et al.
Journal of Medicinal Chemistry|November 21, 1998
(+)-4-[2-[4-(8-Chloro-3,10-dibromo-6,11-dihydro-5H-benzo[5, 6]cyclohepta[1,2-b]- pyridin-11(R)-yl)-1-piperidinyl]-2-oxo-ethyl]-1-piperidinecarboxamid e (SCH-66336): a very potent farnesyl protein transferase inhibitor as a novel antitumor agentF G Njoroge, A G Taveras, J Kelly, et al.
International Journal of Radiation Oncology, Biology, Physics|May 3, 2023
Genomic Classifier Performance in Intermediate-Risk Prostate Cancer: Results From NRG Oncology/RTOG 0126 Randomized Phase 3 TrialDaniel E Spratt, Vinnie Y T Liu, Jeff Michalski, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 16, 2025
Development and Validation of an Artificial Intelligence Digital Pathology Biomarker to Predict Benefit of Long-Term Hormonal Therapy and Radiotherapy in Men With High-Risk Prostate Cancer Across Multiple Phase III TrialsAndrew J Armstrong, Vinnie Y T Liu, Ramprasaath R Selvaraju, et al.
Pageof 23

Showing results (211-220 of 227) with videos related to

Sort By:
Pageof 23
Zhonghua Xue Ye Xue Za Zhi = Zhonghua Xueyexue Zazhi|May 24, 2016
[Cytogentic and prognostic characteristic of acute myeloid leukemia with monosomal karyotype]Z Li, H Wei, D Lin, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 31, 2022
Validation of the Decipher genomic classifier in patients receiving salvage radiotherapy without hormone therapy after radical prostatectomy - an ancillary study of the SAKK 09/10 randomized clinical trialA Dal Pra, P Ghadjar, S Hayoz, et al.
Zhonghua Xue Ye Xue Za Zhi = Zhonghua Xueyexue Zazhi|July 4, 2021
[The characteristics and prognostic impact of NOTCH1/FBXW7 mutation and CDKN2A/B deletion in adult T-cell acute lymphoblastic leukemia patients]Q Y Fang, Q S Hao, X Y Gong, et al.
Zhonghua Xue Ye Xue Za Zhi = Zhonghua Xueyexue Zazhi|July 6, 2026
[Prognostic impact of WT1 mutations in patients with acute myeloid leukemia]Y Zeng, Y Hui, L Yan, et al.
Zhonghua Xue Ye Xue Za Zhi = Zhonghua Xueyexue Zazhi|March 19, 2018
[Characteristics and prognosis in adult acute myeloid leukemia patients with MLL gene rearrangements]X Y Gong, Y Wang, B C Liu, et al.
The Review of Scientific Instruments|December 3, 2016
An instrument for measuring scintillators efficiently based on silicon photomultipliersM J Yang, Z M Zhang, Y J Wang, et al.
International Journal of Radiation Oncology, Biology, Physics|September 25, 2024
Erratum to: Spratt DE, Liu VYT, Michalski J, Davicioni E, Berlin A, Simko JP, Efstathiou JA, Tran PT, Sandler HM, Hall WA, Thompson DJS, Parliament MB, Dayes IS, Correa RJM, Robertson JM, Gore EM, Doncals DE, Vigneault E, Souhami L, Karrison TG, Feng FY. Genomic classifier performance in intermediate-risk prostate cancer: results from NRG Oncology/RTOG 0126 randomized phase 3 trial. Int J Radiat Oncol Biol Phys 2023;117:370-377Daniel E Spratt, Vinnie Y T Liu, Jeff Michalski, et al.
Journal of Medicinal Chemistry|November 21, 1998
(+)-4-[2-[4-(8-Chloro-3,10-dibromo-6,11-dihydro-5H-benzo[5, 6]cyclohepta[1,2-b]- pyridin-11(R)-yl)-1-piperidinyl]-2-oxo-ethyl]-1-piperidinecarboxamid e (SCH-66336): a very potent farnesyl protein transferase inhibitor as a novel antitumor agentF G Njoroge, A G Taveras, J Kelly, et al.
International Journal of Radiation Oncology, Biology, Physics|May 3, 2023
Genomic Classifier Performance in Intermediate-Risk Prostate Cancer: Results From NRG Oncology/RTOG 0126 Randomized Phase 3 TrialDaniel E Spratt, Vinnie Y T Liu, Jeff Michalski, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 16, 2025
Development and Validation of an Artificial Intelligence Digital Pathology Biomarker to Predict Benefit of Long-Term Hormonal Therapy and Radiotherapy in Men With High-Risk Prostate Cancer Across Multiple Phase III TrialsAndrew J Armstrong, Vinnie Y T Liu, Ramprasaath R Selvaraju, et al.
Pageof 23